Rossari Biotech Posts 19% Revenue Growth in Q2FY27 Alongside Saudi Expansion
Rossari Biotech Ltd 路 Investor Presentation 路 19 Oct 2026, 6:07 am
Rossari Biotech Posts 19% Revenue Growth in Q2FY27 Alongside Saudi Expansion Rossari Biotech reported Q2FY27 consolidated revenue of Rs. 697.6 crores, up 19.0% YoY, while EBITDA rose 20.9% YoY to Rs. 87.0 crores with margins at 12.5%. PAT grew 5.4% YoY to Rs. 38.9 crores, moderated by higher project depreciation. Exports surged 33.8% YoY to Rs. 216.4 crores. By segment, HPPC grew 18%, TSC 26%, and AHN 11% YoY. H1FY27 net debt declined to Rs. 221 crores from Rs. 281 crores in Mar'26, and working capital reduced to 86 days. The board approved leasing land for a greenfield facility in Saudi Arabia.
Original exchange filing (PDF)
More announcements from Rossari Biotech Ltd
- Intimation of Transcript of Q2 & H1 FY27 for the Earnings Conference Call held on October 19, 2026 路 23 Oct 2026
- Audio recording of Earnings Conference Call for Q2 & H1 FY 27. 路 20 Oct 2026
- Press Release for Q2 FY27 Results 路 19 Oct 2026
- Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026. 路 18 Oct 2026
- Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 路 18 Oct 2026
- Outcome of Board Meeting held on October 17, 2026. 路 18 Oct 2026
- Outcome of Board Meeting Held On October 17, 2026 路 18 Oct 2026
- Intimation of Earnings Conference Call for investor and analyst on Monday, October 19, 2026 at 04:00 P.M. (IST). 路 19 Oct 2026
